Developer docs
API playgroundTry for free, no card

Search company profiles

Leaf Expression Systems

Full company profile

uuid000rulb

Namestring
Leaf Expression Systems
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Leaf Expression Systems is a privately held contract development and manufacturing organisation (CDMO) headquartered in Norwich, United Kingdom, founded in 2016. The firm operates in the Plant Molecular Farming industry, providing plant-based expression platforms for producing proteins, antibodies, and other therapeutic compounds used by pharmaceutical and biotechnology customers. Its stated core capability is leveraging genetically engineered plants as bioreactors for biologics production — an alternative to mammalian-cell and microbial fermentation systems — with industry-level commentary emphasizing automation and regulatory acceptance of plant-based production methods.

The company is small (1-10 employees) and operates with a lean structure: only two non-executive directors — David Simpson and Simon Aspland — are publicly identified, and there is no disclosed executive leadership team, scientific advisory board, or external investor base in the available sources. No specific named products, services, pricing models, customer logos, partnerships, patents, regulatory certifications, or funding rounds have been disclosed. The firm's public website (leafexpressionsystems.com) is currently non-functional, displaying a cPanel default hosting error page, which limits third-party verification of its commercial activity.

As a CDMO, Leaf Expression Systems is positioned to monetize via development and manufacturing service contracts with biologics developers, but the absence of disclosed revenue, customer references, or deal flow makes the current commercial scale unverifiable from public sources. The broader Plant Molecular Farming market is forecast to grow from USD 485 million in 2025 to USD 1.705 billion in 2035 at a 13.4% CAGR, indicating a sizeable tailwind for the niche if the company is operationally active.

Short descriptiontext

Leaf Expression Systems is a privately held Norwich, UK-based CDMO (founded 2016) that uses plant-based molecular farming platforms to produce proteins, antibodies, and therapeutic compounds for pharmaceutical and biotechnology customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNorwich, United Kingdom
HQ citystring
Norwich
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
plant-based protein expression, contract development manufacturing, plant molecular farming, biopharmaceutical CDMO services, therapeutic protein production
Industry1 code
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Biopharmaceutical Contract Manufacturing
No data
Cost components4 values
Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Leaf Expression Systems is a contract development and manufacturing organisation (CDMO) that uses plant-based expression technologies to produce proteins, antibodies, and other therapeutic compounds through genetically engineered plants for pharmaceutical and biotechnology clients. The company leverages automation and plant molecular farming platforms to deliver biologic production services as an alternative to traditional mammalian or microbial expression systems.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Leaf Expression Systems operates in the Plant Molecular Farming industry, which involves using plant-based production systems for pharmaceutical and biotechnology applications. The company specializes in plant expression technologies for producing proteins, antibodies, and other therapeutic compounds through genetically engineered plants. Based on available source data, no specific named products or modules could be extracted as the primary company website was inaccessible (returning a default hosting error page). The company's core business model involves leveraging automation and plant-based platforms for pharmaceutical production, positioning within a market projected to grow from USD 485 million to USD 1.705 billion at 13.4% CAGR from 2025 to 2035.

Product and service1 record
1Plant-Based Contract Development and Manufacturing Services
CategoryBiopharmaceutical Contract Manufacturing
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Market position
Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Leaf Expression Systems

Biopharmaceutical Contract Manufacturingleafexpressionsystems.com

Leaf Expression Systems is a privately held Norwich, UK-based CDMO (founded 2016) that uses plant-based molecular farming platforms to produce proteins, antibodies, and therapeutic compounds for pharmaceutical and biotechnology customers.

What Leaf Expression Systems does

Leaf Expression Systems is a privately held contract development and manufacturing organisation (CDMO) headquartered in Norwich, United Kingdom, founded in 2016. The firm operates in the Plant Molecular Farming industry, providing plant-based expression platforms for producing proteins, antibodies, and other therapeutic compounds used by pharmaceutical and biotechnology customers. Its stated core capability is leveraging genetically engineered plants as bioreactors for biologics production — an alternative to mammalian-cell and microbial fermentation systems — with industry-level commentary emphasizing automation and regulatory acceptance of plant-based production methods.

The company is small (1-10 employees) and operates with a lean structure: only two non-executive directors — David Simpson and Simon Aspland — are publicly identified, and there is no disclosed executive leadership team, scientific advisory board, or external investor base in the available sources. No specific named products, services, pricing models, customer logos, partnerships, patents, regulatory certifications, or funding rounds have been disclosed. The firm's public website (leafexpressionsystems.com) is currently non-functional, displaying a cPanel default hosting error page, which limits third-party verification of its commercial activity.

As a CDMO, Leaf Expression Systems is positioned to monetize via development and manufacturing service contracts with biologics developers, but the absence of disclosed revenue, customer references, or deal flow makes the current commercial scale unverifiable from public sources. The broader Plant Molecular Farming market is forecast to grow from USD 485 million in 2025 to USD 1.705 billion in 2035 at a 13.4% CAGR, indicating a sizeable tailwind for the niche if the company is operationally active.

Leaf Expression Systems firmographics

Firmographics
Name
Leaf Expression Systems
Website
https://leafexpressionsystems.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Leaf Expression Systems is a privately held Norwich, UK-based CDMO (founded 2016) that uses plant-based molecular farming platforms to produce proteins, antibodies, and therapeutic compounds for pharmaceutical and biotechnology customers.
Ownership category
akta.pro rank

Leaf Expression Systems industry classification

Industry
Product category
Biopharmaceutical Contract Manufacturing
NAICS
Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Plant-based protein expression
  • Contract development manufacturing
  • Plant molecular farming
  • Biopharmaceutical CDMO services
  • Therapeutic protein production

Where Leaf Expression Systems is headquartered

Location

Headquarters

HQ city
Norwich
HQ country
United Kingdom
HQ region
Europe

Markets served

Leaf Expression Systems business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure

Leaf Expression Systems product offering

Product offering

Core offering

Leaf Expression Systems is a contract development and manufacturing organisation (CDMO) that uses plant-based expression technologies to produce proteins, antibodies, and other therapeutic compounds through genetically engineered plants for pharmaceutical and biotechnology clients. The company leverages automation and plant molecular farming platforms to deliver biologic production services as an alternative to traditional mammalian or microbial expression systems.

Product overview

Leaf Expression Systems operates in the Plant Molecular Farming industry, which involves using plant-based production systems for pharmaceutical and biotechnology applications. The company specializes in plant expression technologies for producing proteins, antibodies, and other therapeutic compounds through genetically engineered plants. Based on available source data, no specific named products or modules could be extracted as the primary company website was inaccessible (returning a default hosting error page). The company's core business model involves leveraging automation and plant-based platforms for pharmaceutical production, positioning within a market projected to grow from USD 485 million to USD 1.705 billion at 13.4% CAGR from 2025 to 2035.

Differentiator

Problem solved

Functional benefit

Products and services

  • Plant-Based Contract Development and Manufacturing Services

Companies that use Leaf Expression Systems

Customer profile

Ideal customer profiles1 record

Leaf Expression Systems technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Leaf Expression Systems partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves2 records

Expansion highlights1 record

Leaf Expression Systems competitors and assessment

Company assessment

Market position

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Leaf Expression Systems financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Leaf Expression Systems leadership team

Management profile

Number of profiles

Profiles2 records

Leaf Expression Systems funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Leaf Expression Systems M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Leaf Expression Systems

What does Leaf Expression Systems do?

Leaf Expression Systems is a contract development and manufacturing organisation (CDMO) that uses plant-based expression technologies to produce proteins, antibodies, and other therapeutic compounds through genetically engineered plants for pharmaceutical and biotechnology clients. The company leverages automation and plant molecular farming platforms to deliver biologic production services as an alternative to traditional mammalian or microbial expression systems.

When was Leaf Expression Systems founded?

Leaf Expression Systems was founded in 2016. It employs 1 to 10 people.

Where is Leaf Expression Systems based?

Leaf Expression Systems is headquartered in Norwich, United Kingdom, in the Europe region.

Does Leaf Expression Systems have an API?

No public API is recorded for Leaf Expression Systems.

What industry is Leaf Expression Systems in?

Leaf Expression Systems's product category is Biopharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals